Skip to main content

Truxima News

Anti-CD20 Therapy Shows No Effect on Disability Progression in MS

THURSDAY, Sept. 26, 2024 – For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and...

FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan

July 23, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab),1 for the treatment...

FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan

November 28, 2018 – The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma

Truxima patient information at Drugs.com